Literature DB >> 25380918

Risk factors of acute renal failure after orthotopic liver transplantation: single-center experience.

P Smoter1, P Nyckowski2, M Grat2, W Patkowski2, K Zieniewicz2, K Wronka3, B Hinderer3, M Morawski3.   

Abstract

BACKGROUND: Acute renal failure (ARF) is one of the most significant complications of orthotopic liver transplantation (OLT), associated with increased mortality rate and the development of chronic renal dysfunction. The aim of the study was to determine the perioperative risk factors for ARF in patients without previous history of renal disease who are undergoing OLT.
MATERIALS AND METHODS: Forty-six patients who developed ARF after OLT performed in 1 transplant center were included in the study, and 52 consecutive patients without that complication served as a control group. Renal dysfunction was defined as a glomerular filtration rate <60 mL/min/1.73 m(2). The data concerning preoperative diseases, perioperative renal function, first-line immunosuppressive therapy, and blood transfusion requirement were retrospectively analyzed and compared among groups. Logistic regression modeling was used to determine risk factors for ARF.
RESULTS: Patients who developed ARF were significantly older (mean age 53.3 vs 46.3 years, P = .057), had higher level of preoperative (0.79 vs 0.71 mg/dL, P = .0062) and intraoperative (0.85 vs 0.74 mg/dL, P = .0045) creatinine. The risk factors for ARF were intraoperative and 24-hour post-transplant creatinine level >0.9 mg/dL and high-dose tacrolimus-based immunosuppression. Transfusion of ≤6 units of red blood cells diminished the risk of ARF. Sex and preoperative diseases were not predictive to ARF in our regression models.
CONCLUSION: Careful operative technique with low blood loss and immunosuppressive therapy of low nephrotoxic potential should be recommended in older patients to diminish the risk of renal dysfunction after orthotopic liver transplantation. Patients with higher levels of perioperative creatinine should be considered to have first-line immunosuppression without calcineurin inhibitors or with low-dose immunosuppressants of known nephrotoxic potential.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25380918     DOI: 10.1016/j.transproceed.2014.09.044

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  6 in total

1.  Risk factors for acute kidney injury after orthotopic liver transplantation: A single-center data analysis.

Authors:  Zhi-Qiang Zhou; Long-Chang Fan; Xu Zhao; Wei Xia; Ai-Lin Luo; Yu-Ke Tian; Xue-Ren Wang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2017-12-21

2.  Incidence and outcomes of acute kidney injury in patients with hepatocellular carcinoma after liver transplantation.

Authors:  Xiaohong Chen; Xiaoqiang Ding; Bo Shen; Jie Teng; Jianzhou Zou; Ting Wang; Jian Zhou; Nan Chen; Boheng Zhang
Journal:  J Cancer Res Clin Oncol       Date:  2017-03-13       Impact factor: 4.553

3.  Risk factors of acute kidney injury after orthotopic liver transplantation in China.

Authors:  Yin Zongyi; Li Baifeng; Zou Funian; Li Hao; Wang Xin
Journal:  Sci Rep       Date:  2017-01-30       Impact factor: 4.379

4.  Role of serum levels of intraoperative brain natriuretic peptide for predicting acute kidney injury in living donor liver transplantation.

Authors:  Min Suk Chae; Hyunjoon Park; Ho Joong Choi; Misun Park; Hyun Sik Chung; Sang Hyun Hong; Chul Soo Park; Jong Ho Choi; Hyung Mook Lee
Journal:  PLoS One       Date:  2018-12-17       Impact factor: 3.240

5.  High-dose ulinastatin to prevent late-onset acute renal failure after orthotopic liver transplantation.

Authors:  Haijin Lv; Xuxia Wei; Xiaomeng Yi; Jianrong Liu; Pinglan Lu; Mi Zhou; Yuling An; Huimin Yi
Journal:  Ren Fail       Date:  2020-11       Impact factor: 2.606

6.  Effects of perioperative fluid management on postoperative outcomes in liver transplantation: a systematic review protocol.

Authors:  François Martin Carrier; Michaël Chassé; Han Ting Wang; Pierre Aslanian; Marc Bilodeau; Alexis F Turgeon
Journal:  Syst Rev       Date:  2018-10-31
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.